Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.81 |
| ▸ | PPARG | P37231 | 7/20 | 0.81 |
| ▸ | PPARD | Q03181 | 7/20 | 0.81 |
| ▸ | PPARA | Q07869 | 7/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.81 |
| ▸ | FABP4 | P15090 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | TLR2 | O60603 | 2/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.81 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptadecanoic Acid SCHEMBL380301 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL21694820 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Behenic Acid SCHEMBL6742157 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL8614032 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL21694821 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL21694824 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Myristic Acid SCHEMBL8613744 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL380300 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL22688948 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL12276002 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025530-A | Polylactic acid, biodegradable composition, and preparation method and application thereof | 江苏金发科技新材料有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-117447683-B | Polylactic acid and preparation method and application thereof | 金发科技股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-118888759-A | Positive electrode slurry, positive electrode sheet and electrochemical device comprising positive electrode sheet | 远景动力技术(鄂尔多斯市)有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-117447683-A | Polylactic acid and preparation method and application thereof | 金发科技股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-110437884-B | Method for hydrogen production and power generation through biomass charcoal catalysis | 吉林大学 | 2020-09-01 | — | — | CN | claimed |
| CN-110437884-A | A kind of method of biomass carbon catalyzing manufacturing of hydrogen power generation | UNIV JILIN | 2019-11-12 | — | — | CN | claimed |
| CN-110202293-A | A kind of high-performance halogen-free leadless soldering tin paste and preparation method thereof | 何雪连 | 2019-09-06 | — | — | CN | claimed |
| CN-110156966-A | Poly- (2- hydroxyl alkane acid) and preparation method thereof | 普拉克生化公司 | 2019-08-23 | — | — | CN | claimed |
| US-20190099342-A1 | COOLING PRODUCT | SYMRISE AG (DE) | 2019-04-04 | — | — | US | claimed |
| EP-2885334-B1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC BIOCHEM BV (NL) | 2018-12-05 | — | — | EP | claimed |
| EP-3194468-A1 | A METHOD FOR STABILIZING A CONDENSED PHASE COMPOSITION INCLUDING A CYCLIC ESTER IN A PROCESS OF MANUFACTURING A POLYESTER OR OF LACTIDE | Sulzer Chemtech AG (CH) | 2017-07-26 | — | — | EP | claimed |
| CN-106715523-A | A method for stabilizing a condensed phase composition including a cyclic ester in a process of manufacturing a polyester or of lactide | 苏舍化学技术有限公司 | 2017-05-24 | — | — | CN | claimed |
| CN-103448132-B | A kind of flame retardant type concrete composite wallboard and preparation method thereof | 安徽省中坤元新型建材有限公司 | 2016-07-27 | — | — | CN | claimed |
| WO-2016041722-A1 | A METHOD FOR STABILIZING A CONDENSED PHASE COMPOSITION INCLUDING A CYCLIC ESTER IN A PROCESS OF MANUFACTURING A POLYESTER OR OF LACTIDE | SULZER CHEMTECH AG (CH) | 2016-03-24 | — | — | WO | claimed |
| EP-2998337-A1 | A method for stabilizing a condensed phase composition including a cyclic ester for example in a process of manufacturing a polyester | Sulzer Chemtech AG (CH) | 2016-03-23 | — | — | EP | claimed |
| CN-104937008-A | Poly (2-hydroxyalkanoic acid) and method for producing same | PURAC BIOCHEM BV | 2015-09-23 | — | — | CN | claimed |
| EP-2885334-A1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC Biochem BV (NL) | 2015-06-24 | — | — | EP | claimed |
| WO-2014027037-A1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC BIOCHEM BV (NL) | 2014-02-20 | — | — | WO | claimed |
| EP-2698394-A1 | Poly(2-hydroxyalkanoic acid) and method of its manufacture | PURAC Biochem BV (NL) | 2014-02-19 | — | — | EP | claimed |
| JP-5242733-A | — | — | None | — | — | JP | disclosed |
| EP-4006103-B1 | POLYESTER RESIN COMPOSITION AND MOLDED PRODUCT THEREOF | TORAY INDUSTRIES (JP) | 2025-11-05 | — | — | EP | disclosed |
| CN-120025530-A | Polylactic acid, biodegradable composition, and preparation method and application thereof | 江苏金发科技新材料有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-117447683-B | Polylactic acid and preparation method and application thereof | 金发科技股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-116731775-B | Refrigerating cycle device, refrigerating machine oil, and refrigerant leakage preventing agent | 大金工业株式会社 | 2025-02-18 | — | — | CN | disclosed |
| CN-118888759-B | Positive electrode slurry, positive electrode sheet and electrochemical device comprising positive electrode sheet | 远景动力技术(鄂尔多斯市)有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119119344-A | Acrylic ester emulsion and preparation method thereof | 广东巴德富新材料有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118888759-A | Positive electrode slurry, positive electrode sheet and electrochemical device comprising positive electrode sheet | 远景动力技术(鄂尔多斯市)有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240237643-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | SYMRISE AG (DE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148083-A1 | SOLID FORMS OF A CDK2 INHIBITOR | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148087-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148089-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-07-04 | — | — | US | disclosed |
| EP-4387587-A1 | COMPOSITIONS | Symrise AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| CN-118159632-A | Perfume and perfume mixture | 西姆莱斯股份公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024110515-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110023-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2024-05-30 | — | — | WO | disclosed |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | SYMRISE AG (DE) | 2024-05-30 | — | — | US | disclosed |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | PFIZER, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024104625-A1 | A BLEND OF EMOLLIENTS | SYMRISE AG (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024104546-A1 | A BLEND OF EMOLLIENTS | SYMRISE AG (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024097436-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4363423-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| EP-4355742-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240122834-A1 | MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024078679-A1 | A FRAGRANCE MIXTURE (VI) | SYMRISE AG (DE) | 2024-04-18 | — | — | WO | disclosed |
| US-20240124808-A1 | POLYUREA MICROCAPSULES AND LIQUID SURFACTANT SYSTEMS CONTAINING THEM | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117813077-A | Composition and method for producing the same | 西姆莱斯股份公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117813300-A | Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors | 缆图药品公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113693965-B | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024061476-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2024-03-28 | — | — | WO | disclosed |
| US-11938208-B2 | Antimicrobial mixture | SYMRISE AG (DE) | 2024-03-26 | — | — | US | disclosed |
| CN-113710331-B | Antimicrobial mixture | 西姆莱斯股份公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024051922-A1 | A FRAGRANCE MIXTURE (III) | SYMRISE AG (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024046834-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4331564-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4330265-A1 | MICROBIAL GLYCOLIPIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11911347-B2 | Compositions comprising one or more (bio)-alkanediols with antioxidants | SYMRISE AG (DE) | 2024-02-27 | — | — | US | disclosed |
| WO-2024037712-A1 | 1-CYCLOOCTYLPROPAN-2-ONE AS A FRAGRANCE | SYMRISE AG (DE) | 2024-02-22 | — | — | WO | disclosed |
| US-20240058243-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | SYMRISE AG (DE) | 2024-02-22 | — | — | US | disclosed |
| EP-4322911-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | Symrise AG (DE) | 2024-02-21 | — | — | EP | disclosed |
| US-20240050337-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | SYMRISE AG (DE) | 2024-02-15 | — | — | US | disclosed |
| WO-2024028513-A1 | ODOR AND COLORANT STABILIZED COMPOSITIONS | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028512-A1 | COMPOSITIONS COMPRISING AN ANTIMICROBIAL BOOSTING AGENT | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027930-A1 | COMPOSITIONS COMPRISING AN ANTIMICROBIAL BOOSTING AGENT | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027922-A1 | A FRAGRANCE MIXTURE (II) | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027931-A1 | ODOR AND COLORANT STABILIZED COMPOSITIONS | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | disclosed |
| EP-4314220-A1 | A LIQUID DETERGENT COMPOSITION | Symrise AG (DE) | 2024-02-07 | — | — | EP | disclosed |
| CN-117447683-A | Polylactic acid and preparation method and application thereof | 金发科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4308286-A1 | ACTIVE SUBSTANCE CAPSULES | Symrise AG (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240009106-A1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS LLC | 2024-01-11 | — | — | US | disclosed |
| EP-4301833-A1 | TOILET RIM BLOCKS WITH SCENT CHANGE | Symrise AG (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-4291154-A1 | MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION | Symrise AG (DE) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023232242-A1 | FRAGRANCE MIXTURE | SYMRISE AG (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232245-A1 | FRAGRANCES WITH CYCLOPROPYL STRUCTURE | SYMRISE AG (DE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023232243-A1 | A FRAGRANCE MIXTURE (V) | SYMRISE AG (DE) | 2023-12-07 | — | — | WO | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230364027-A1 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | AG, SYMRISE (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023213386-A1 | A FRAGRANCE MIXTURE (V) | SYMRISE AG (DE) | 2023-11-09 | — | — | WO | disclosed |
| CN-116997316-A | Perfume mixture containing isochronic alcohol (Isocitronellol) | 西姆莱斯股份公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116964186-A | Toilet edge block with smell change | 西姆莱斯股份公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116963710-A | Medicine for preventing and treating hyperpigmentation | 西姆莱斯股份公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338250-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Active Ingredients | SYMRISE AG (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230329994-A1 | Surfactant Containing Formulation of Pseudo-Ceramides | SYMRISE AG (DE) | 2023-10-19 | — | — | US | disclosed |
| EP-4259088-A1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABINOIDS | Symrise AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259287-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | Symrise AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116890516-A | Recording method and recording device | 精工爱普生株式会社 | 2023-10-17 | — | — | CN | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116806825-A | Antimicrobial mixture | 西姆莱斯股份公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230293408-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230293407-A1 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023175129-A1 | ADDITIVE FOR SUNSCREENS | SYMRISE AG (DE) | 2023-09-21 | — | — | WO | disclosed |
| US-20230293404-A1 | Compositions Comprising Natural Polymers and One or More (Bio)-Alkanediols | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230293409-A1 | Compositions Comprising Antimicrobials and (Bio)-Alkanediols for Skin Protection | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| EP-4245292-A1 | ADDITIVE FOR SUNSCREENS | Symrise AG (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-4245291-A1 | ADDITIVE FOR SUNSCREENS | Symrise AG (DE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023169695-A1 | HAIR CARE COMPOSITION | SYMRISE AG (DE) | 2023-09-14 | — | — | WO | disclosed |
| US-11752085-B2 | Keratin-based hair straightening formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116731775-A | Refrigerating cycle device, refrigerating machine oil, and refrigerant leakage preventing agent | 大金工业株式会社 | 2023-09-12 | — | — | CN | disclosed |
| CN-116685300-A | Composition comprising one or more (bio) -alkanediols with an antioxidant | 西姆莱斯股份公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023160805-A1 | FRAGRANCES WITH METHOXY ACETATE STRUCTURE | SYMRISE AG (DE) | 2023-08-31 | — | — | WO | disclosed |
| CN-116634990-A | Compositions comprising one or more (bio) -alkanediols with active ingredients | 西姆莱斯股份公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11723850-B2 | Liquid and transparent blend of UV filters | Symrise, AG (DE) | 2023-08-15 | — | — | US | disclosed |
| CN-116583261-A | Method for combating microorganisms using menthol derivatives | 西姆莱斯股份公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230248663-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | SYMRISE AG (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2023147852-A1 | COMPOSITIONS (III) | SYMRISE AG (DE) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023147874-A1 | A FRAGRANCE MIXTURE | SYMRISE AG (DE) | 2023-08-10 | — | — | WO | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-116546961-A | Composition for product protection comprising (bio) -alkanediol and antimicrobial agent | 西姆莱斯股份公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116490160-A | A mixture containing 1, 2-alkanediol | 西姆莱斯股份公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-113543637-B | Antimicrobial mixture | 西姆莱斯股份公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114867828-B | Refrigerating cycle device, refrigerating machine oil, and refrigerant leakage preventing agent | 大金工业株式会社 | 2023-07-14 | — | — | CN | disclosed |
| CN-116348086-A | Surfactant-containing formulations of ceramide | 西姆莱斯股份公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159854-A1 | A FRAGRANCE COMPOSITION | SYMRISE AG (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2023088551-A1 | FRAGRANCES AND FRAGRANCE MIXTURES | SYMRISE AG (DE) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023083445-A1 | COMPOSITIONS COMPRISING TRPM8 AGONISTIC COOLING AGENTS | SYMRISE AG (DE) | 2023-05-19 | — | — | WO | disclosed |
| EP-4178356-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | Symrise AG (DE) | 2023-05-17 | — | — | EP | disclosed |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115942870-A | Composition with virucidal and/or antiviral activity | 西姆莱斯股份公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-4149919-A1 | A FRAGRANCE COMPOSITION | Symrise AG (DE) | 2023-03-22 | — | — | EP | disclosed |
| US-20230059747-A1 | A COOLING PREPARATION | SYMRISE AG (DE) | 2023-02-23 | — | — | US | disclosed |
| WO-2023021012-A1 | COMPOSITIONS | SYMRISE AG (DE) | 2023-02-23 | — | — | WO | disclosed |
| EP-4134426-A1 | NOVEL BACTERIAL FERMENT OF LACTOBACILLUS SPECIES | Symrise AG (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230044140-A1 | RIM BLOCK WITH IMPROVED SCENT PERFORMANCE | SYMRISE AG (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4110276-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS | Symrise AG (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4110476-A1 | COMPOSITIONS COMPRISING ANTIMICROBIALS AND (BIO)-ALKANEDIOLS FOR SKIN PROTECTION | Symrise AG (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4110477-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS | Symrise AG (DE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115551828-A | Perfume composition | 西姆莱斯股份公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266190-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103143-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | Symrise AG (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103288-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION | Symrise AG (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022207944-A9 | NOVEL MIXTURES AND USES OF (2E)-3-(1,3-BENZODIOXOL-5-YL)-N-PHENYL-N-(TETRAHYDRO-3-FURANYL)-2-PROPENAMIDE | SYMRISE AG (DE) | 2022-12-15 | — | — | WO | disclosed |
| EP-4096618-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | Symrise AG (DE) | 2022-12-07 | — | — | EP | disclosed |
| CN-111225662-B | Pharmaceutical compositions and dosage forms | 伊尼塔公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220354775-A1 | NOVEL BACTERIAL FERMENT OF LACTOBACILLUS SPECIES | SYMRISE AG (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220354772-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | SYMRISE AG (DE) | 2022-11-10 | — | — | US | disclosed |
| CN-115305215-A | Novel bacterial starter of the genus lactobacillus | 西姆莱斯股份公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11491091-B2 | Cooling product | SYMRISE AG (DE) | 2022-11-08 | — | — | US | disclosed |
| WO-2022184247-A1 | TOILET RIM BLOCKS WITH SCENT CHANGE | SYMRISE AG (DE) | 2022-09-09 | — | — | WO | disclosed |
| US-20220275199-A1 | POLYESTER RESIN COMPOSITION AND MOLDED PRODUCT THEREOF | TORAY INDUSTRIES, INC. (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-4045179-A1 | POLYUREA MICROCAPSULES AND LIQUID SURFACTANT SYSTEMS CONTAINING THEM | Symrise AG (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4025675-A1 | A PERFUME OIL MIXTURE | Symrise AG (DE) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727914-A | Product for the indirect transfer of a cosmetic active to the skin | 西姆莱斯股份公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728254-A | Polyurea microcapsules and liquid surfactant system containing the same | 西姆莱斯股份公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728092-A | Edge block with improved odor performance | 西姆莱斯股份公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022128054-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN (IV) | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128052-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128048-A1 | MEDICAMENT FOR PREVENTING OR TREATING PATHOLOGIC CONDITIONS OF HUMAN SKIN | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128057-A1 | MEDICAMENT FOR PREVENTION AND TREATMENT OF COLLAGEN DEGRADATION IN HUMAN CONNECTING TISSUE | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128390-A1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABINOIDS | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128051-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN (II) | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128050-A1 | MEDICAMENT FOR FIGHTING INFLAMMATION AND PAIN | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013404-A1 | METHODS OF TREATING CANCER | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022122167-A1 | MEDICAMENT FOR PREVENTING OR TREATING PATHOLOGIC CONDITIONS OF HUMAN SKIN (I) | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122135-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122136-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122143-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122935-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122890-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122896-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122898-A1 | COMPOSITIONS COMPRISING ANTIMICROBIALS AND (BIO)-ALKANEDIOLS FOR SKIN PROTECTION | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122144-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122122-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN (I) | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122140-A1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ACTIVE INGREDIENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122132-A1 | COMPOSITIONS COMPRISING NATURAL POLYMERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122930-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122137-A1 | COMPOSITIONS COMPRISING ANTIMICROBIALS AND (BIO)-ALKANEDIOLS FOR SKIN PROTECTION | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | disclosed |
| US-20220183937-A1 | METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURE | SYMRISE AG (DE) | 2022-06-16 | — | — | US | disclosed |
| US-20220168198-A1 | AN ANTIMICROBIAL MIXTURE | SYMRISE AG (DE) | 2022-06-02 | — | — | US | disclosed |
| WO-2022111829-A1 | ESSENTIAL OILS OF CITRUS FRUITS FOR USE AS MEDICAMENT FOR INDUCED, INCREASED AND/OR ACCELERATED AUTOPHAGY IN HUMAN KERATINOCYTES | SYMRISE AG (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111793-A1 | MEDICAMENT FOR ACCELERATED WOUND HEALING | SYMRISE AG (DE) | 2022-06-02 | — | — | WO | disclosed |
| EP-4006103-A1 | POLYESTER RESIN COMPOSITION AND MOLDED PRODUCT THEREOF | Toray Industries, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-3993767-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | Symrise AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3986365-A1 | SURFACTANT CONTAINING FORMULATION OF PSEUDO-CERAMIDES | Symrise AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20220117881-A1 | A HAIR CARE COMPOSITION | SYMRISE AG (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3982910-A1 | A COOLING PREPARATION | Symrise AG (DE) | 2022-04-20 | — | — | EP | disclosed |
| CN-109789144-B | Protein kinase modulators | 马德拉医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364773-A | Aromatic oil mixture | 西姆莱斯股份公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-114222576-A | Methods of treating cancer | F·霍夫曼-罗氏股份公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114126579-A | Mixture of beeswax and lactoyl lactate | 西姆莱斯股份公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220047476-A1 | A METHOD FOR FIGHTING FEMALE BODY ODORS | SYMRISE AG (DE) | 2022-02-17 | — | — | US | disclosed |
| CN-114007697-A | Antiproliferative agents for the treatment of PAH | 辉瑞公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993500-A | Cool preparation | 德国德之馨香精香料公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3941434-A1 | PLANT PEPTIDES AND THEIR APPLICATIONS (II) | Symrise AG (DE) | 2022-01-26 | — | — | EP | disclosed |
| EP-3938054-A1 | A METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURE | Symrise AG (DE) | 2022-01-19 | — | — | EP | disclosed |
| EP-3938055-A1 | AN ANTIMICROBIAL MIXTURE | Symrise AG (DE) | 2022-01-19 | — | — | EP | disclosed |
| WO-2022008088-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | SYMRISE AG (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2022003575-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-3930714-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113891750-A | Method for improving performance of spice or spice mixture | 西姆莱斯股份公司 | 2022-01-04 | — | — | CN | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| CN-113795251-A | Use of casein hydrolyzing protease P function as a biomarker of drug response to IMIPRIDONE-like agents | 马德拉治疗公司 | 2021-12-14 | — | — | CN | disclosed |
| EP-3917913-A2 | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2 | Pfizer Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113766911-A | Plant peptides and uses thereof (II) | 西姆莱斯股份公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-113710331-A | Antimicrobial mixture | 西姆莱斯股份公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113693965-A | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3911159-A1 | AN ANTIMICROBIAL MIXTURE | Symrise AG (DE) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021228840-A1 | A FRAGRANCE COMPOSITION | SYMRISE AG (DE) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021228352-A1 | A FRAGRANCE COMPOSITION | SYMRISE AG (DE) | 2021-11-18 | — | — | WO | disclosed |
| CN-109135200-B | Polybutylene terephthalate resin composition and molded article | 三菱工程塑料株式会社 | 2021-11-09 | — | — | CN | disclosed |
| CN-109310585-B | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113543637-A | Antimicrobial mixture | 西姆莱斯股份公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| EP-3496724-B1 | PROTEIN KINASE REGULATORS | NANJING GATOR MEDITECH COMPANY LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-3877494-A1 | AN ANTIMICROBIAL SURFACTANT BASED COMPOSITION | Symrise AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021176349-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | PFIZER INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-3873622-A1 | A LIQUID AND TRANSPARENT BLEND OF UV FILTERS | Symrise AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| CN-113330000-A | 3-carbonylamino-5-cyclopentyl-1 FI-pyrrole compound having inhibitory activity against CDK2 | 辉瑞公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11091477-B2 | Protein kinase regulators | Madera Therapeutics, LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091483-B2 | Protein kinase regulators | Madera Therapeutics, LLC (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3860721-A1 | A METHOD FOR FIGHTING FEMALE BODY ODORS | Symrise AG (DE) | 2021-08-11 | — | — | EP | disclosed |
| CN-112384568-B | Polyester resin composition and molded product thereof | 东丽先端材料研究开发（中国）有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113226267-A | Hair care composition | 西姆莱斯股份公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113164792-A | Liquid transparent mixtures of UV filters | 西姆莱斯股份公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3849505-A1 | A HAIR CARE COMPOSITION | Symrise AG (DE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3834827-A1 | N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO) BENZAMIDE FOR TREATING PATIENTS WITH ROS1,NTRK1, NTRK2 AND NTRK3 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112955230-A | A method for resisting female body odor | 西姆莱斯股份公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3576757-B1 | METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY | NOVARTIS AG (CH) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021104645-A1 | RIM BLOCK WITH IMPROVED SCENT PERFORMANCE | SYMRISE AG (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11007191-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2021073775-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021073774-A1 | POLYUREA MICROCAPSULES AND LIQUID SURFACTANT SYSTEMS CONTAINING THEM | SYMRISE AG (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210113555-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2021043585-A1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2021-03-11 | — | — | WO | disclosed |
| EP-3784664-A1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | Pfizer Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112384568-A | Polyester resin composition and molded product thereof | 东丽先端材料研究开发（中国）有限公司 | 2021-02-19 | — | — | CN | disclosed |
| WO-2021030619-A1 | METHODS OF TREATING CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| US-10920070-B2 | Poly(butylene terephthalate) composition and associated article | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2021-02-16 | — | — | US | disclosed |
| CN-112313219-A | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2021013115-A1 | POLYESTER RESIN COMPOSITION AND MOLDED PRODUCT THEREOF | 东丽先端材料研究开发（中国）有限公司 | 2021-01-28 | — | — | WO | disclosed |
| WO-2021001029-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | SYMRISE AG (DE) | 2021-01-07 | — | — | WO | disclosed |
| EP-3758753-A1 | COMBINATION OF A CYCLIN DEPENDENT KINASE INHIBITOR AND A BET-BROMODOMAIN INHIBITOR | Pfizer Inc (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200405809-A1 | COMBINATION OF A CYCLIN DEPENDENT KINASE INHIBITOR AND A BET- BROMODOMAIN INHIBITOR | PFIZER INC. (US) | 2020-12-31 | — | — | US | disclosed |
| EP-3107541-B1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10869864-B2 | Combinations for the treatment of cancer | IGNYTA, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020249216-A1 | A COOLING PREPARATION | SYMRISE AG (DE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10799503-B2 | Methods for the treatment of cancer | IGNYTA, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2020192864-A1 | PLANT PEPTIDES AND THEIR APPLICATIONS (II) | SYMRISE AG (DE) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192865-A1 | PLANT PEPTIDES AND THEIR APPLICATIONS | SYMRISE AG (DE) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020182318-A1 | AN ANTIMICROBIAL MIXTURE | SYMRISE AG (DE) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020182288-A1 | A METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURE | SYMRISE AG (DE) | 2020-09-17 | — | — | WO | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| CN-110437884-B | Method for hydrogen production and power generation through biomass charcoal catalysis | 吉林大学 | 2020-09-01 | — | — | CN | disclosed |
| EP-3697390-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | Ignyta, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2020157652-A2 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200237756-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. | 2020-07-30 | — | — | US | disclosed |
| WO-2020147953-A1 | AN ANTIMICROBIAL MIXTURE | SYMRISE AG (DE) | 2020-07-23 | — | — | WO | disclosed |
| CN-107667145-B | Poly (butylene terephthalate) compositions and related articles | SABIC环球技术有限责任公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200181139-A1 | Protein Kinase Regulators | Madera Therapeutics, LLC | 2020-06-11 | — | — | US | disclosed |
| EP-3659576-A1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | Baum, Marc Michael (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-111225662-A | Pharmaceutical compositions and dosage forms | 伊尼塔公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-111225886-A | Interlayer film for laminated glass and laminated glass | 积水化学工业株式会社 | 2020-06-02 | — | — | CN | disclosed |
| US-20200163892-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3654952-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTRECTINIB | Ignyta, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3648753-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2020-05-13 | — | — | EP | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| WO-2020069762-A1 | A METHOD FOR FIGHTING FEMALE BODY ODORS | SYMRISE AG (DE) | 2020-04-09 | — | — | WO | disclosed |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| EP-3303476-B1 | POLY(BUTYLENE TEREPHTHALATE) COMPOSITION AND ASSOCIATED ARTICLE | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2020-04-01 | — | — | EP | disclosed |
| CN-110913842-A | Pharmaceutical compositions comprising enretinib | 伊尼塔公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2020052778-A1 | A HAIR CARE COMPOSITION | SYMRISE AG (DE) | 2020-03-19 | — | — | WO | disclosed |
| US-20200069688-A1 | METHODS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10570121-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10561651-B2 | Methods for treating neuroblastoma | IGNYTA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200049714-A1 | METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| US-20200046626-A1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS LLC | 2020-02-13 | — | — | US | disclosed |
| CN-106715523-B | Method for stabilizing condensed phase compositions comprising cyclic esters in a process for the manufacture of polyesters or lactides | 苏舍化学技术有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-106604963-B | Vinyl chloride resin stabiliser compositions, vinyl chloride resin composition and its formed products containing the stabiliser compositions | ADEKA株式会社 | 2019-11-26 | — | — | CN | disclosed |
| CN-110461342-A | The method for predicting the reaction to immunotherapy | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| CN-110437884-A | A kind of method of biomass carbon catalyzing manufacturing of hydrogen power generation | UNIV JILIN | 2019-11-12 | — | — | CN | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
| CN-107207464-B | Substituted dihydro-isoquinoline ketone compound | 辉瑞大药厂 | 2019-10-22 | — | — | CN | disclosed |
| EP-3548007-A1 | METHODS FOR THE TREATMENT OF CANCER | Ignyta, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10434053-B2 | Keratin-based hair straightening formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| CN-110191705-A | Methods of treating cancer | 亚尼塔公司 | 2019-08-30 | — | — | CN | disclosed |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| CN-110156966-A | Poly- (2- hydroxyl alkane acid) and preparation method thereof | 普拉克生化公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-106715522-B | By the continuation method of cyclic ester monomer manufacture polyester | 苏舍化学技术有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-10376457-B2 | Keratin-based hair straightening formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3521285-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190224200-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| EP-2694834-B1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BAUM MARC MICHAEL (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3503887-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | Ignyta, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185567-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3496724-A1 | PROTEIN KINASE REGULATORS | Nanjing Gator Meditech Company, Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-20190177323-A1 | Protein Kinase Regulators | Madera Therapeutics, LLC | 2019-06-13 | — | — | US | disclosed |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-3490561-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | Ignyta, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-109789144-A | Protein kinase modulators | 南京盖特医药技术有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109715162-A | Protein kinase modulators | 南京盖特医药技术有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715157-A | Combination for treating cancer | 亚尼塔公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109689056-A | Combination for treating cancer | 亚尼塔公司 | 2019-04-26 | — | — | CN | disclosed |
| WO-2019077506-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| CN-109641993-A | Epoxy-modified vinyl based copolymer, the thermoplastic resin composition comprising the copolymer and its molded product | 大科能宇菱通株式会社 | 2019-04-16 | — | — | CN | disclosed |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2019-04-11 | — | — | US | disclosed |
| US-20190099342-A1 | COOLING PRODUCT | SYMRISE AG (DE) | 2019-04-04 | — | — | US | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| CN-104761585-B | The substituted-amino pyrimidine of inhibitor as EGFR tyrosine kinase | 北京轩义医药科技有限公司 | 2019-03-26 | — | — | CN | disclosed |
| US-10231965-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| CN-104761544-B | The selective depressant of the important mutant of clinic of EGFR tyrosine kinase | 北京轩义医药科技有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109384650-A | 1, 2-alkanediol and process for producing the same | 西姆莱斯股份公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109328059-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-20190040047-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| CN-109310585-A | External preparation for skin for improving wrinkles | 宝丽化成工业有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3434330-A1 | A METHOD FOR ENHANCING THE COOLING EFFECT OF A COOLING COMPOUND | Symrise AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2019018570-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTRECTINIB | IGNYTA, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| US-20190022089-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2019010295-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2019-01-10 | — | — | WO | disclosed |
| CN-109135200-A | Polybutylene terephthalate based resin composition and formed body | 三菱工程塑料株式会社 | 2019-01-04 | — | — | CN | disclosed |
| US-20190000840-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2885334-B1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC BIOCHEM BV (NL) | 2018-12-05 | — | — | EP | disclosed |
| US-20180333412-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| EP-3389645-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | Ignyta, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-108697661-A | Combination for treating cancer | 亚尼塔公司 | 2018-10-23 | — | — | CN | disclosed |
| EP-3383912-A1 | TOPICAL FORMULATIONS | Ignyta, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180256570-A1 | TOPICAL FORMULATIONS | IGNYTA, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| CN-108495862-A | Topical formulations | 亚尼塔公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108473484-A | Compounds useful as TRPM8 modulators | 赛诺米克斯公司 | 2018-08-31 | — | — | CN | disclosed |
| US-10059799-B2 | Method for stabilizing a condensed phase composition including a cyclic ester in a process of manufacturing a polyester or of lactide | SULZER CHEMTECH AG (CH) | 2018-08-28 | — | — | US | disclosed |
| WO-2018145023-A1 | METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY | NOVARTIS AG (CH) | 2018-08-09 | — | — | WO | disclosed |
| EP-3356356-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018138591-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| CN-104918997-B | Polybutylene terephthalate resin composition and molded article | 三菱工程塑料株式会社 | 2018-07-31 | — | — | CN | disclosed |
| WO-2018119418-A1 | METHODS RELATING TO THE TREATMENT OF CHEMORESISTANT AND IMMUNO-RESISTANT CANCER | NIVIEN THERAPEUTICS COMPANY (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180163043-A1 | POLY(BUTYLENE TEREPHTHALATE) COMPOSITION AND ASSOCIATED ARTICLE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-06-14 | — | — | US | disclosed |
| CN-108137796-A | Poly (butylene terephthalate) processes and related compositions and articles | SABIC环球技术有限责任公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2018102455-A1 | METHODS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3303476-A1 | POLY(BUTYLENE TEREPHTHALATE) COMPOSITION AND ASSOCIATED ARTICLE | SABIC Global Technologies B.V. (NL) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018039275-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018031987-A1 | PROTEIN KINASE REGULATORS | NANJING GATOR MEDITECH COMPANY, LTD. (CN) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018026663-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| CN-107667145-A | poly (butylene terephthalate) compositions and related articles | SABIC环球技术有限责任公司 | 2018-02-06 | — | — | CN | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| CN-106029800-B | Metal surface coating composition and the covered electric cable with terminal using said composition | 株式会社自动网络技术研究所 | 2017-12-19 | — | — | CN | disclosed |
| US-20170356918-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | IGNYTA, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3227686-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| CN-107207464-A | Substituted dihydro-isoquinoline assimilation compound | 辉瑞大药厂 | 2017-09-26 | — | — | CN | disclosed |
| CN-104748422-B | Refrigerating plant | 大金工业株式会社 | 2017-09-08 | — | — | CN | disclosed |
| US-20170240700-A1 | A Method for Stabilizing a Condensed Phase Composition Including a Cyclic Ester in a Process of Manufacturing a Polyester or of Lactide | SULZER CHEMTECH AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-9732071-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3194468-A1 | A METHOD FOR STABILIZING A CONDENSED PHASE COMPOSITION INCLUDING A CYCLIC ESTER IN A PROCESS OF MANUFACTURING A POLYESTER OR OF LACTIDE | Sulzer Chemtech AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017106492-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017095757-A1 | TOPICAL FORMULATIONS | IGNYTA, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-9670314-B2 | Poly(2-hydroxyalkanoic acid) and method of its manufacture | PURAC BIOCHEM B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| CN-106715523-A | A method for stabilizing a condensed phase composition including a cyclic ester in a process of manufacturing a polyester or of lactide | 苏舍化学技术有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-106715522-A | A continuous method for manufacturing a polyester from cyclic ester monomer | 苏舍化学技术有限公司 | 2017-05-24 | — | — | CN | disclosed |
| EP-3157915-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| CN-106604963-A | Stabilizer composition for vinyl chloride resin, vinyl chloride resin composition using said stabilizer composition, and molded article obtained from said resin composition | ADEKA株式会社 | 2017-04-26 | — | — | CN | disclosed |
| CN-104955896-B | Resin composition for laser direct structuring, molded resin article, and method of manufacturing molded resin article having plating film | 三菱工程塑料株式会社 | 2017-04-19 | — | — | CN | disclosed |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-04-06 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3107541-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| CN-104870435-B | Aryl and heteroaryl-condensed lactams | 辉瑞大药厂 | 2016-12-07 | — | — | CN | disclosed |
| WO-2016188890-A1 | POLY(BUTYLENE TEREPHTHALATE) COMPOSITION AND ASSOCIATED ARTICLE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2016-12-01 | — | — | WO | disclosed |
| CN-104619774-B | Resin composition for laser direct structuring, resin molded article, and method for producing resin molded article having plated layer | 三菱工程塑料株式会社 | 2016-11-16 | — | — | CN | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-106029073-A | Compounds for treating patients with ROS1 mutant cancer cells | 亚尼塔公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160214996-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | WELL NOVA LIMITED (VG) | 2016-07-28 | — | — | US | disclosed |
| CN-103448132-B | A kind of flame retardant type concrete composite wallboard and preparation method thereof | 安徽省中坤元新型建材有限公司 | 2016-07-27 | — | — | CN | disclosed |
| EP-3041364-A1 | USE OF AN ANTI-CAKING AGENT FOR IMPROVING THE HARDNESS OF CHEWING-GUM CONTAINING MALTITOL IN A POWDERY FORM | Roquette Frères (FR) | 2016-07-13 | — | — | EP | disclosed |
| CN-104105758-B | Polyester and resin composition and molded body thereof | 株式会社吴羽 | 2016-07-06 | — | — | CN | disclosed |
| WO-2016089853-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160158138-A1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS LLC | 2016-06-09 | — | — | US | disclosed |
| CN-104169286-B | Be used for the treatment of the macrocyclic derivatives of proliferative diseases | 辉瑞大药厂 | 2016-06-08 | — | — | CN | disclosed |
| WO-2016073771-A2 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016041722-A1 | A METHOD FOR STABILIZING A CONDENSED PHASE COMPOSITION INCLUDING A CYCLIC ESTER IN A PROCESS OF MANUFACTURING A POLYESTER OR OF LACTIDE | SULZER CHEMTECH AG (CH) | 2016-03-24 | — | — | WO | disclosed |
| EP-2998337-A1 | A method for stabilizing a condensed phase composition including a cyclic ester for example in a process of manufacturing a polyester | Sulzer Chemtech AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2935238-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2015-10-08 | — | — | US | disclosed |
| CN-104937008-A | Poly (2-hydroxyalkanoic acid) and method for producing same | PURAC BIOCHEM BV | 2015-09-23 | — | — | CN | disclosed |
| CN-104918997-A | Polybutylene terephthalate resin composition and molded article | MITSUBISHI ENG PLASTICS CORP | 2015-09-16 | — | — | CN | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015124697-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2015-08-27 | — | — | US | disclosed |
| CN-104870435-A | Aryl and heteroaryl fused lactams | PFIZER | 2015-08-26 | — | — | CN | disclosed |
| EP-2900653-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | Pfizer Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150210802-A1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | SULZER MANAGEMENT AG. (CH) | 2015-07-30 | — | — | US | disclosed |
| CN-104748422-A | FREEZING DEVICE | DAIKIN IND LTD | 2015-07-01 | — | — | CN | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2015092614-A1 | ACTIVATING NOTCH ALTERATIONS IN BREAST CANCER | PFIZER INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2885334-A1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC Biochem BV (NL) | 2015-06-24 | — | — | EP | disclosed |
| CN-104023990-B | Resin composition for laser direct structuring, resin-molded article, and method for manufacturing molded article with plated layer | MITSUBISHI ENGINERRING PLASTICS CORP | 2015-06-10 | — | — | CN | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2015050989-A2 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CS THERAPEUTICS INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015028763-A1 | USE OF AN ANTI-CAKING AGENT FOR IMPROVING THE HARDNESS OF CHEWING-GUM CONTAINING MALTITOL IN A POWDERY FORM | ROQUETTE FRERES (FR) | 2015-03-05 | — | — | WO | disclosed |
| EP-2822953-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Pfizer Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| CN-103277941-B | Refrigeration apparatus | DAIKIN IND LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-104169286-A | Macrocyclic derivatives for the treatment of proliferative diseases | PFIZER | 2014-11-26 | — | — | CN | disclosed |
| US-20140299149-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | COOLWAY INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140261517-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | COOLWAY INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-104017153-A | Polylactic acid resin composition | MITSUI CHEMICALS INC | 2014-09-03 | — | — | CN | disclosed |
| CN-104017152-A | Stereocomplex polylactic acid resin composition and process for producing stereocomplex polylactic acid resin composition | MITSUI CHEMICALS INC | 2014-09-03 | — | — | CN | disclosed |
| CN-104023990-A | Resin composition for laser direct structuring, resin-molded article, and method for manufacturing molded article with plated layer | MITSUBISHI ENGINERRING PLASTICS CORP | 2014-09-03 | — | — | CN | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| CN-102459391-B | Polylactic acid resin, method for producing polylactic acid resin, polylactic acid resin composition, stereocomplex polylactic acid resin composition, and method for producing stereocomplex polylactic acid resin composition | MITSUI CHEMICALS INC | 2014-07-09 | — | — | CN | disclosed |
| US-8771658-B2 | Compositions and methods for treating keratin based fibers | COOLWAY INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103764139-A | Combination of motesanib, a taxane and a platinum-containing anticancer agent for the treatment of non-small cell lung cancer in a subset of the population | AMGEN INC | 2014-04-30 | — | — | CN | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2014027037-A1 | POLY(2-HYDROXYALKANOIC ACID) AND METHOD OF ITS MANUFACTURE | PURAC BIOCHEM BV (NL) | 2014-02-20 | — | — | WO | disclosed |
| EP-2698394-A1 | Poly(2-hydroxyalkanoic acid) and method of its manufacture | PURAC Biochem BV (NL) | 2014-02-19 | — | — | EP | disclosed |
| EP-2694834-A2 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | Baum, Marc Michael (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8623950-B2 | High heat and chlorine resistant polyurethaneurea elastic fiber and preparation of thereof | TAE KWANG IND. CO., LTD. (KR) | 2014-01-07 | — | — | US | disclosed |
| US-20130340785-A1 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS LLC | 2013-12-26 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| CN-103277941-A | Refrigeration apparatus | DAIKIN IND LTD | 2013-09-04 | — | — | CN | disclosed |
| EP-2627305-A2 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | Coolway Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130202543-A1 | USE OF POLYOLS FOR ENHANCING THE COOLING EFFECT OF A COOLING SUBSTANCE AND COOLING MIXTURES HAVING AN ENHANCED COOLING EFFECT | SYMRISE AG (DE) | 2013-08-08 | — | — | US | disclosed |
| CN-101724936-B | High heat and chlorine resistant polyurethaneurea elastic fiber and preparation of thereof | TAE KWANG IND CO LTD | 2013-07-17 | — | — | CN | disclosed |
| EP-2591787-A1 | Combination motif immune stimulatory oligonucleotides with improved activity | Pfizer Inc (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2579950-A2 | USE OF POLYOLS FOR ENHANCING THE COOLING EFFECT OF A COOLING SUBSTANCE AND COOLING MIXTURES HAVING AN ENHANCED COOLING EFFECT | Symrise AG (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-8414872-B2 | Hair straightening formulations, methods and systems | LIQUID KERATIN, INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| EP-2163581-B1 | POLYESTER RESIN COMPOSITION FOR INJECTION MOLDING, LIGHT REFLECTOR BASE, AND LIGHT REFLECTOR | MITSUBISHI ENG PLASTICS CORP (JP) | 2012-09-26 | — | — | EP | disclosed |
| WO-2012122457-A2 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | BAUM MARC MICHAEL (US) | 2012-09-13 | — | — | WO | disclosed |
| CN-101489528-B | Cell-activating agent, collagen production-promoting agent, bleaching agent, anti-oxidizing agent, anti-inflammatory agent, aromatase activity-promoting agent, protease activity-promoting agent, skin topical agent and food | NOEVIR KK | 2012-09-05 | — | — | CN | disclosed |
| US-20120219571-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8198251-B2 | Combination motif immune stimulatory oligonucleotides with improved activity | COLEY PHARMACEUTICAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| CN-102459391-A | Polylactic acid resin, method for producing polylactic acid resin, polylactic acid resin composition, stereocomplex polylactic acid resin composition, and method for producing stereocomplex polylactic acid resin composition | MITSUI CHEMICALS INC | 2012-05-16 | — | — | CN | disclosed |
| WO-2012051629-A2 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | MANEWORX INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120093755-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | MANEWORX INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8097602-B1 | Method of treating body insect infestation | HOST PHARMACEUTICALS, LLC (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2356120-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| US-7989631-B2 | Antiangiogenic drug AMG 706 hydrate phosphate salt; AMG 706 is known as motesanib, or N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; oral administration; suspension; cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110152460-A1 | SYNDIOTACTIC PROPYLENE BASED POLYMER COMPOSITION, FORMED BODY, AND LAMINATED SHEET | MITSUI CHEMICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110092628-A1 | High Heat and Chlorine Resistant Polyurethaneurea Elastic Fiber and Preparation of Thereof | TAE KWANG IND. CO., LTD. (KR) | 2011-04-21 | — | — | US | disclosed |
| US-20110007410-A1 | POLYESTER RESIN COMPOSITION FOR INJECTION-MOLDING, LIGHT REFLECTOR BASE AND LIGHT REFLECTOR | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2010149798-A2 | USE OF POLYOLS FOR ENHANCING THE COOLING EFFECT OF A COOLING SUBSTANCE AND COOLING MIXTURES HAVING AN ENHANCED COOLING EFFECT | SYMRISE AG (DE) | 2010-12-29 | — | — | WO | disclosed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| EP-2209771-A1 | CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES | Pfizer, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2200563-A1 | HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | Resnick, Lionel (US) | 2010-06-30 | — | — | EP | disclosed |
| CN-101724936-A | High heat and chlorine resistant polyurethaneurea elastic fiber and preparation of thereof | TAE KWANG IND CO LTD | 2010-06-09 | — | — | CN | disclosed |
| EP-2190440-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | Pfizer Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| WO-2010050639-A1 | HIGH HEAT AND CHLORINE RESISTANT POLYURETHANEUREA ELASTIC FIBER AND PREPARATION OF THEREOF | TAE KWANG IND.CO., LTD. (KR) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010038165-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2163581-A1 | POLYESTER RESIN COMPOSITION FOR INJECTION MOLDING, LIGHT REFLECTOR BASE, AND LIGHT REFLECTOR | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009105617-A1 | METHOD OF TREATING BODY INSECT INFESTATION | HOST PHARMACEUTICALS, LLC (US) | 2009-08-27 | — | — | WO | disclosed |
| CN-101489528-A | Cell-activating agent, collagen production-promoting agent, bleaching agent, anti-oxidizing agent, anti-inflammatory agent, aromatase activity-promoting agent, protease activity-promoting agent, skin | NOEVIR KK (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-20090165812-A1 | HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | LIQUID KERATIN, INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| WO-2009065090-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RESPONSIVE TO PROTEASOME INHIBITION | UNIVERSITY OF HAWAII (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009060278-A1 | CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES | PFIZER INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090087446-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | COLEY PHARMACEUTICAL GMBH | 2009-04-02 | — | — | US | disclosed |
| WO-2009035970-A1 | HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS | RESNICK LIONEL (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009022215-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | PFIZER INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2007423-A2 | CTLA4 ANTIBODY COMBINATION THERAPY | Pfizer Products Incorporated (US) | 2008-12-31 | — | — | EP | disclosed |
| US-RE40534-E1 | Clear conditioning detersive compositions containing polysiloxanes with at least one cyclic side chain | CHEMSIL SILICONES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080039501-A1 | Antiangiogenic drug AMG 706 hydrate phosphate salt; AMG 706 is known as motesanib, or N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; oral administration; suspension; cancer | AMGEN INC. (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1123994-B1 | ELASTOMERIC POLYURETHANE FIBER | ASAHI CHEMICAL IND (JP) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| CN-101115505-A | Methods and compositions for treating mammalian diseases and wounds caused by peroxynitrite overexpression | NORTH CELL PHARMACEUTICAL INC (US) | 2008-01-30 | — | — | CN | disclosed |
| CN-101098753-A | Use of metal complexes with bispyridylpyrimidine or bispyridyltriazine ligands as catalysts for reactions with peroxides for bleaching coloured stains on hard surfaces | CIBA SC HOLDING AG (CH) | 2008-01-02 | — | — | CN | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| WO-2007113648-A2 | CTLA4 ANTIBODY COMBINATION THERAPY | PFIZER PRODUCTS INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007066189-A2 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20060106164-A1 | Antistatic agent and coating or molding synthetic resins | SUZUKA FUJI XEROX CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595931-A1 | ANTISTATIC AGENT AND COATING OR MOLDING SYNTHETIC RESINS | Suzuka Fuji Xerox Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| CN-1571706-A | Ultrasonic cleaning product comprising cleaning composition with dissolved gas | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | CN | disclosed |
| US-6762250-B2 | TRANSPARENCY, FLUIDITY; CONTAINING POLYSILOXANE HAVING AT LEAST AROMATIC HYDROCARBON FUNCTIONALITY, CARBOXYLIC ACID ESTER AND/OR ETHER LINKAGES AND PHOSPHORIC ESTER GROUP ATTACHMENT | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20040054116-A1 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-6642194-B2 | Clear hair shampoo composition comprising detersive component, emulsifier component and polysiloxane component in amount effective as hair conditioner | CHEMSIL SILICONES, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6605577-B1 | Having a hindered amine group; hair shampoo | CHEMSIL SILICONES, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030134760-A1 | Clear conditioning detersive compositions and methods for making the same | CHEMSIL SILICONES, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030022799-A1 | A SHAMPOO FOAMING COMPOSITION WHICH COMPRISES AN ALKYL ETHER SULFATE, A SORBITAN DERIVATIVE, A BETAINE, AN ALKYLAMIDO ALKYLAMINE, AN ALKOXYLATED CARBOXYLIC ACID, AND AN ORGANIC SALT | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6406788-B1 | BLEND CONTAINING METAL COMPOUND | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1123994-A1 | ELASTOMERIC POLYURETHANE FIBER | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-5372988-A | Thermal transfer printing dyesheet | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-13 | — | — | US | disclosed |
| JP-H05242733-A | ELECTRICALLY INSULATING MATERIAL | HITACHI CABLE LTD | 1993-09-21 | — | — | JP | disclosed |
| US-5178949-A | Microcapsule with colorless dye, hydrophobic solvent, oil soluble nonionic surfactant | JUJO PAPER CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| US-5178949-A | Microcapsule with colorless dye, hydrophobic solvent, oil soluble nonionic surfactant | JUJO PAPER CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766884-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | GPR84 4472/4885PPARG 3446/4885PPARD 4565/4885 |
| US-11491091-B2 | Cooling product | TRPA1, TRPV2, TRPV1 | GPR84 4441/4885PPARG 302/4885PPARD 265/4885 |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | GPR84 632/4885PPARG 778/4885PPARD 723/4885 |
| US-20230059747-A1 | A COOLING PREPARATION | GPX4, HTR3C, ADH1C | GPR84 3073/4885PPARG 609/4885PPARD 905/4885 |
| US-20190099342-A1 | COOLING PRODUCT | TRPA1, TRPV2, NISCH | GPR84 4329/4885PPARG 487/4885PPARD 448/4885 |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | GPR84 3001/4885PPARG 4192/4885PPARD 4652/4885 |
| US-20230293408-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | MMP8, CXCL8, IL18 | GPR84 2294/4885PPARG 582/4885PPARD 632/4885 |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | TTBK1, TTK, TTBK2 | GPR84 4627/4885PPARG 3679/4885PPARD 3247/4885 |
| US-20190185567-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | TYRO3, MERTK, MET | GPR84 598/4885PPARG 2188/4885PPARD 2754/4885 |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | GPR84 1128/4885PPARG 145/4885PPARD 276/4885 |
| US-11091477-B2 | Protein kinase regulators | MAP3K1, MAP3K6, MAP3K20 | GPR84 3136/4885PPARG 1832/4885PPARD 1867/4885 |
| US-20240122834-A1 | MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION | MC1R, OR51E2, TYR | GPR84 106/4885PPARG 235/4885PPARD 743/4885 |
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | GPR84 4309/4885PPARG 3264/4885PPARD 3440/4885 |
| US-10570121-B2 | Substituted dihydroisoquinolinone compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS, TP53 | GPR84 2044/4885PPARG 3716/4885PPARD 4326/4885 |
| US-20210113555-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | ROS1, NTRK3, NTRK1 | GPR84 733/4885PPARG 2570/4885PPARD 3174/4885 |
| US-20240058243-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | MGLL, GCDH, GK | GPR84 468/4885PPARG 569/4885PPARD 244/4885 |
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | GPR84 3518/4885PPARG 3971/4885PPARD 3886/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | GPR84 3337/4885PPARG 2725/4885PPARD 3539/4885 |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | GPR84 3001/4885PPARG 4192/4885PPARD 4652/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | GPR84 4309/4885PPARG 3264/4885PPARD 3440/4885 |
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | UGCG, SGMS1, GPR119 | GPR84 408/4885PPARG 349/4885PPARD 371/4885 |
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | GPR84 4643/4885PPARG 415/4885PPARD 749/4885 |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | CDK4, CDK2, CDK6 | GPR84 3145/4885PPARG 1862/4885PPARD 2317/4885 |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | GPR84 2768/4885PPARG 543/4885PPARD 1494/4885 |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | CUTA, POLR1C, SLC16A7 | GPR84 4697/4885PPARG 1934/4885PPARD 1910/4885 |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | GPR84 4472/4885PPARG 3446/4885PPARD 4565/4885 |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | GPR84 3001/4885PPARG 4192/4885PPARD 4652/4885 |
| US-20230364027-A1 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | AKR7A2, HAAO, ABHD5 | GPR84 4258/4885PPARG 837/4885PPARD 488/4885 |
| US-20120219571-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | STING1, IFNG, RNGTT | GPR84 1014/4885PPARG 1986/4885PPARD 3227/4885 |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PIK3CA, PIK3CD, PIK3R5 | GPR84 2351/4885PPARG 2074/4885PPARD 1228/4885 |
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | NEK2, CSNK1G3, AHNAK | GPR84 3903/4885PPARG 2186/4885PPARD 3592/4885 |
| US-10869864-B2 | Combinations for the treatment of cancer | ROS1, NTRK3, NTRK1 | GPR84 733/4885PPARG 2570/4885PPARD 3174/4885 |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | GPR84 3191/4885PPARG 3486/4885PPARD 2600/4885 |
| US-20220183937-A1 | METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURE | CUTA, DEGS1, DHCR24 | GPR84 3390/4885PPARG 1102/4885PPARD 821/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | GPR84 1213/4885PPARG 2523/4885PPARD 3489/4885 |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | GPR84 2915/4885PPARG 1641/4885PPARD 1549/4885 |
| US-11007191-B2 | Pharmaceutical compositions and dosage forms | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, CYP3A5 | GPR84 4665/4885PPARG 321/4885PPARD 781/4885 |
| US-20200163892-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | GPR84 4643/4885PPARG 415/4885PPARD 749/4885 |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | CDKN1A, DPYD, SLC14A1 | GPR84 4614/4885PPARG 965/4885PPARD 537/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | GPR84 441/4885PPARG 102/4885PPARD 62/4885 |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | GPR84 1298/4885PPARG 2026/4885PPARD 3443/4885 |
| US-11938208-B2 | Antimicrobial mixture | GNPAT, GMDS, DDOST | GPR84 2883/4885PPARG 167/4885PPARD 1137/4885 |
| US-20190224200-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | MET, TYRO3, MERTK | GPR84 1252/4885PPARG 897/4885PPARD 1358/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | GPR84 1126/4885PPARG 2403/4885PPARD 1161/4885 |
| US-20170356918-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | TP53, BRCA1, MKI67 | GPR84 3797/4885PPARG 4393/4885PPARD 4302/4885 |
| US-20220354772-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | LAGE3, CRY1, BROX | GPR84 3370/4885PPARG 4556/4885PPARD 4598/4885 |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM4, TRPM6 | GPR84 435/4885PPARG 1285/4885PPARD 938/4885 |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | GPR84 1741/4885PPARG 2608/4885PPARD 3616/4885 |
| US-10561651-B2 | Methods for treating neuroblastoma | UBTF, CABLES1, WEE2 | GPR84 3575/4885PPARG 885/4885PPARD 2757/4885 |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | STT3A, CLSPN, STT3B | GPR84 3904/4885PPARG 3753/4885PPARD 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.